Disc Medicine Inc (nasdaq:IRON) Share Price

Company Profile

Business description
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Contact
321 Arsenal Street
Suite 101
WatertownMA02472
USA
T: +1 617 674-9274
https://www.discmedicine.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
165

Recommended

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.

Seth Goldstein, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,882.00	35.10	-0.39%
CAC 40	7,811.26	110.42	-1.39%
DAX 40	25,371.75	273.29	-1.07%
Dow JONES (US)	52,867.98	11.89	0.02%
FTSE 100	10,725.03	27.85	-0.26%
HKSE	22,934.68	717.19	-3.03%
NASDAQ	26,008.86	694.00	-2.60%
Nikkei 225	62,159.41	748.43	-1.19%
NZX 50 Index	13,709.78	37.06	-0.27%
S&P 500	7,663.43	93.74	-1.21%
S&P/ASX 200	8,768.30	24.90	-0.28%
SSE Composite Index	3,658.03	55.00	-1.48%